Ameriprise’s Akero Therapeutics AKRO Stock Holding History

Ameriprise’s Portfolio AKRO Stock Details AKRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-291,593	Closed	-$13.8M	–	4075
2025 Q3	$13.8M	Buy	291,593 +18,148	+7%	+$879K	﹤0.01%	1663
2025 Q2	$14.6M	Buy	273,445 +193,978	+244%	+$8.81M	﹤0.01%	1543
2025 Q1	$3.22M	Buy	79,467 +64,295	+424%	+$2.73M	﹤0.01%	2628
2024 Q4	$422K	Buy	+15,172	New	+$459K	﹤0.01%	3590
2024 Q2	–	Sell	-8,578	Closed	-$217K	–	3858
2024 Q1	$217K	Sell	8,578 -238,315	-97%	-$5.72M	﹤0.01%	3667
2023 Q4	$5.76M	Buy	246,893 +226,255	+1,096%	+$4.46M	﹤0.01%	2242
2023 Q3	$1.04M	Buy	20,638 +15,191	+279%	+$707K	﹤0.01%	3125
2023 Q2	$254K	Sell	5,447 -185	-3%	-$8.48K	﹤0.01%	3656
2023 Q1	$215K	Sell	5,632 -8,873	-61%	-$396K	﹤0.01%	3711
2022 Q4	$794K	Sell	14,505 -84,228	-85%	-$3.61M	﹤0.01%	3230
2022 Q3	$3.36M	Buy	+98,733	New	+$1.51M	﹤0.01%	2508

Other funds holding AKRO

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Ameriprise's AKRO Position: Q4 2025 in Review

Ameriprise sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 291,593 shares — an estimated $13.8M sold.

Ameriprise first reported a position in AKRO in Q3 2022 and held it in 11 quarters. The position peaked at $14.6M in Q2 2025. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.

Ameriprise reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
Ameriprise sold 291,593 Akero Therapeutics shares in Q4 2025, an estimated $13.8M.
Ameriprise first reported a position in Akero Therapeutics in Q3 2022 and held it in 11 quarters.
Ameriprise's Akero Therapeutics position peaked at $14.6M in Q2 2025.
2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.

Based on Ameriprise's 13F filing for Q4 2025, filed 17 Feb 2026.